Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688180 Shanghai Junshi Biosciences Co.,Ltd.

Closed 12-19 15:00:01

35.41

-0.12

-0.34%

High35.91	Low34.60	Vol8.12M
Open35.18	D1 Closing35.53	Amplitude3.69%
Mkt Cap36.37B	Tradable Cap27.12B	Total Shares1.03B
T/O287.00M	T/O Rate1.06%	Tradable Shares766.00M
P/B5.85	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"Shanghai Junshi Biosciences Co.,Ltd.","latestPrice":35.41,"timestamp":1766127601000,"preClose":35.53,"halted":0,"volume":8124968,"delay":0,"changeRate":-0.0034,"floatShares":766000000,"shares":1027000000,"eps":-0.9252,"marketStatus":"Closed","change":-0.12,"latestTime":"12-19 15:00:01","open":35.18,"high":35.91,"low":34.6,"amount":287000000,"amplitude":0.0369,"askPrice":35.41,"askSize":118,"bidPrice":35.39,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.9252,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":35.53,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":39.08,"lowLimit":31.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1026689871,"isCdr":false,"pbRate":5.85,"roa":"--","roe":"--","epsLYR":-1.3,"committee":-0.89011,"marketValue":36355000000,"turnoverRate":0.0106,"status":1,"afterMarket":{"amount":0,"volume":0,"close":35.41,"buyVolume":0,"sellVolume":0,"time":1766129639585,"indexStatus":"Closed 12-19 15:30:00","preClose":35.53},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"JUNSHI BIO","latestPrice":23.24,"timestamp":1766131686004,"preClose":22.48,"halted":0,"volume":2941400,"delay":0,"premium":"-40.65"},"floatMarketCap":27138000000},"requestUrl":"/m/hq/s/688180/tweets","defaultTab":"tweets","newsList":[{"id":"2592997758","title":"BRIEF-Junshi Biosciences' Shareholder To Unload Up To 2% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997758","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997758?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:55","pubTimestamp":1766055304,"startTime":"0","endTime":"0","summary":"BRIEF-Junshi Biosciences' Shareholder To Unload Up To 2% StakeDec 18 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:SAYS SHAREHOLDER PLANS TO UNLOAD UP TO 2% STAKE IN COSource textFurther company coverage: 688180.SS (Reporting by Beijing Newsroom) ((Xiuhao.Chen@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2592797730","title":"Shanghai Junshi Biosciences  Says Shareholder Plans to Unload up to 2% Stake in Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2592797730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592797730?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:55","pubTimestamp":1766055304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2591697940","title":"Shanghai Junshi Biosciences Gets US FDA Approval for Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697940","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591697940?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:35","pubTimestamp":1765776943,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  obtained the approval of the U.S. Food and Drug Administration for the clinical trial application for JS212 to treat advanced solid tumors.JS212 is designed to target both epidermal growth factor receptor and human epidermal growth factor receptor 3, which are commonly overexpressed in lung and colorectal cancers, according to a Monday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1583","688180","01877","BK0239","BK1161"],"gpt_icon":0},{"id":"1186550543","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 4% as FDA Approves JS212 Clinical Trial for Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1186550543","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186550543?lang=en_us&edition=fundamental","pubTime":"2025-12-15 09:50","pubTimestamp":1765763413,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged more than 4%, reaching HK$25 by the time of writing, with a trading volume of HK$34.83 million. The rise follows the company's announcement on December 14 that the U.S. Food...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK1161","01877","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2591367663","title":"FDA Approves IND Application for Shanghai Junshi Biosciences’ JS212","url":"https://stock-news.laohu8.com/highlight/detail?id=2591367663","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591367663?lang=en_us&edition=fundamental","pubTime":"2025-12-14 18:54","pubTimestamp":1765709683,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co. Ltd. announced that it has received approval from the U.S. Food and Drug Administration  for its investigational new drug  application for JS212, an EGFR/HER3 bispecific antibody-drug conjugate. This approval allows the company to commence clinical studies of JS212 for the treatment of advanced solid tumors. No other organizations are mentioned as receiving the regulatory approval alongside Shanghai Junshi Biosciences Co. Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 14, 2025, and is solely responsible fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nNDLc3gphv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2590533142","title":"BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2590533142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590533142?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:41","pubTimestamp":1765377687,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Says Chairman Xiong Jun Intended To Increase Shareholding In A And H Shares For Up To RMB100 MLNDec 10  - Shanghai Junshi Biosciences Co Ltd 688180.SS:CHAIRMAN XIONG JUN INTENDED TO INCREASE SHAREHOLDING IN A SHARES AND H SHARES FOR NO LESS THAN RMB100 MILLIONFurther company coverage: 688180.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK1583","01877","BK1515","BK1161","BK0239"],"gpt_icon":0},{"id":"2590819125","title":"Shanghai Junshi Biosciences -  Chairman Xiong Jun Intended to Increase Shareholding in a Shares and H Shares for No Less Than RMB100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2590819125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590819125?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:58","pubTimestamp":1765367887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1583","BK1515","688180","BK1161","01877"],"gpt_icon":0},{"id":"2589038430","title":"Junshi Biosciences' Application for Plaque Psoriasis Drug Gets China Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2589038430","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589038430?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:28","pubTimestamp":1765175328,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  new drug application for the roconkibart injection was accepted by China's National Medical Products Administration, a Dec. 5 Hong Kong bourse filing said.Shares of the healthcare company were up 1% in Monday afternoon trading.The drug is for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688180","BK1161","01877","BK0239","BK1583","BK1515"],"gpt_icon":0},{"id":"2589384823","title":"Junshi Biosciences' Four Drugs Placed on China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384823","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589384823?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:23","pubTimestamp":1765174985,"startTime":"0","endTime":"0","summary":"Four drugs under Shanghai Junshi Biosciences  were included in China's  National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Sunday disclosure on the Hong Kong bourse.The pharmaceutical company's Shanghai and Hong Kong shares both rose less than 1% during Monday's afternoon trade.The drugs included on the list are toripalimab injection or Tuoyi, adalimumab injection or Junmaikang, deuremidevir hydrobromide tablets or Mindewei, and ongericimab injection or Junshida.Tuoyi is the only anti-PD-1 monoclonal antibody on the list for the treatment of renal cancer, triple-negative breast cancer and melanoma.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","688180","BK1515","01877","BK1583","BK0239"],"gpt_icon":0},{"id":"1185043125","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1185043125","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185043125?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:38","pubTimestamp":1765157897,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK1515","01877","BK1161","BK1583","BK0239"],"gpt_icon":0},{"id":"2589712468","title":"Shanghai Junshi Biosciences Wins NRDL Inclusion for New Indications of TUOYI and JUNSHIDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589712468","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589712468?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:17","pubTimestamp":1765102669,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co. Ltd. announced that two new indications for its products Toripalimab Injection  and Ongericimab Injection  have been successfully included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance  for 2025. The updated NRDL, which will take effect on January 1, 2026, is expected to enhance accessibility and expand market coverage for these therapies in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 07, 2025, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL4dj71F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2589841661","title":"Junshi Biosciences Reports Toripalimab Achieves Record Survival in NPC and ESCC Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841661","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841661?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990691,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. announced new long-term survival results from the JUPITER-02 and JUPITER-06 clinical trials, evaluating toripalimab in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma  and advanced or metastatic esophageal squamous cell carcinoma , respectively. The updated data, including the 5-year overall survival follow-up from JUPITER-02, were presented at the European Society for Medical Oncology  Asia Congress 2025. The JUPITER-02 trial enrolled 289 chemotherapy-nave patients with recurrent or metastatic NPC, randomizing them to receive either toripalimab or placebo with gemcitabine and cisplatin, followed by monotherapy until disease progression or other discontinuation criteria. The primary endpoint was progression-free survival, with overall survival as a key secondary endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT stri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL6dq5Rj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","BK0239","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","688180","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2589154368","title":"Junshi Biosciences Announces Acceptance of the Nda for Roconkibart (Il-17a) for the Treatment of Moderate to Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589154368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589154368?lang=en_us&edition=fundamental","pubTime":"2025-12-05 23:19","pubTimestamp":1764947990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUA16J5FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2589137278","title":"BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2589137278","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589137278?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:51","pubTimestamp":1764946319,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Junshi Biosciences Says Acceptance Of New Drug ApplicationDec 5 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:ACCEPTANCE OF NEW DRUG APPLICATION FOR ROCONKIBART INJECTION BY NMPAFurther company coverage: 688180.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","688180","BK0239","BK1161","BK1583","01877"],"gpt_icon":0},{"id":"2589342892","title":"Shanghai Junshi Biosciences Receives Acceptance for Roconkibart Injection NDA for Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589342892","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589342892?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:33","pubTimestamp":1764938010,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co. Ltd. announced that its new drug application  for roconkibart injection, a recombinant humanized anti-IL-17A monoclonal antibody intended for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, has been accepted by the National Medical Products Administration. This marks a significant step in the regulatory review process for the company's new pharmaceutical product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 05, 2025, and is sole","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLb888Mp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180"],"gpt_icon":0},{"id":"2589892346","title":"Shanghai Junshi Biosciences - Acceptance of New Drug Application for Roconkibart Injection by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892346?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:33","pubTimestamp":1764938006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1161","BK1583","01877","BK1515","688180"],"gpt_icon":0},{"id":"1145157960","title":"Shanghai Junshi Biosciences (688180.SH): Nuo Kao Qi Monoclonal Antibody Injection's New Drug Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1145157960","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145157960?lang=en_us&edition=fundamental","pubTime":"2025-12-05 17:34","pubTimestamp":1764927260,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (688180.SH) announced that it recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The new drug application...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","688180","BK1583","BK1515","BK0239","BK1161"],"gpt_icon":0},{"id":"1155375642","title":"JUNSHI BIO (01877) Plans to Utilize Idle Raised Funds for Cash Management","url":"https://stock-news.laohu8.com/highlight/detail?id=1155375642","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155375642?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:34","pubTimestamp":1764243250,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) announced that the company will strictly control risks in accordance with relevant regulations and intends to invest temporarily idle raised funds in safe, highly liquid...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1515","688180","01877","BK0239","BK1161"],"gpt_icon":0},{"id":"2586428642","title":"Shanghai Junshi Biosciences Board Approves Cash Management Using Temporarily Idle Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586428642?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:24","pubTimestamp":1764242655,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co. Ltd. held the fifteenth meeting of the fourth session of its Board of Directors on 27 November 2025. At the meeting, the board approved the \"Proposal on Cash Management by Using Temporarily Idle Proceeds.\" Under this resolution, the company is authorized to manage a portion of its temporarily idle raised funds by investing in principal-guaranteed, highly secure, and liquid financial products such as call deposits, fixed deposits, agreement deposits, portfolio deposits, certificates of deposit, and structured deposits. The approval is valid for 12 months from the date of the board's decision, and the funds may be used on a revolving basis within this period. This matter does not require approval at the general meeting.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL9lKC4R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688180","BK0239"],"gpt_icon":0},{"id":"1162501983","title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 5% Again as Toripalimab Subcutaneous Injection Phase III Trial Meets Primary Endpoint, Plans Submission for Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1162501983","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162501983?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:12","pubTimestamp":1764126733,"startTime":"0","endTime":"0","summary":"JUNSHI BIO (01877) surged more than 5% again, with shares up 4.43% to HK$25.48 at the time of writing, recording a turnover of HK$46.15 million. The company announced that its self-developed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1583","III","BK4134","688180","01877","BK0239","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1925},{"period":"6month","weight":0.076},{"period":"1year","weight":0.1855},{"period":"ytd","weight":0.3}],"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","perCapita":"21361股","boardName":"医药制造业","registeredCapital":"102668万元","compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"survey":"　　上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主，同时通过合作开发、设立合资企业以及许可（license-in）等形式引进与自有源创产品线有协同作用的药物或平台技术，进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”，并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。","serverTime":1766149865499,"listedPrice":55.5,"stockholders":"35877人(较上一季度增加15.17%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Junshi Biosciences Co.,Ltd.(688180) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Junshi Biosciences Co.,Ltd.,688180,Shanghai Junshi Biosciences Co.,Ltd.股票,Shanghai Junshi Biosciences Co.,Ltd.股票老虎,Shanghai Junshi Biosciences Co.,Ltd.股票老虎国际,Shanghai Junshi Biosciences Co.,Ltd.行情,Shanghai Junshi Biosciences Co.,Ltd.股票行情,Shanghai Junshi Biosciences Co.,Ltd.股价,Shanghai Junshi Biosciences Co.,Ltd.股市,Shanghai Junshi Biosciences Co.,Ltd.股票价格,Shanghai Junshi Biosciences Co.,Ltd.股票交易,Shanghai Junshi Biosciences Co.,Ltd.股票购买,Shanghai Junshi Biosciences Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Junshi Biosciences Co.,Ltd.(688180),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Junshi Biosciences Co.,Ltd.(688180) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}